Xanthigen® is a proprietary botanical ingredient developed by Nektium for use in nutraceutical and dietary supplement formulations focused on weight management. The ingredient combines a wakame brown seaweed-derived component with pomegranate seed oil. Its formulation brings together fucoxanthin-associated botanical material and lipid components derived from pomegranate seeds.
The ingredient is designed for formulators and nutraceutical brands looking for a differentiated botanical ingredient for product development. Its exact composition, standardization, recommended use level, physical form, stability profile, and technical specifications should be confirmed using the current manufacturer-approved technical data sheet.
Wakame is a brown seaweed identified botanically as Undaria pinnatifida. Brown seaweeds contain various naturally occurring compounds, including fucoxanthin, a carotenoid pigment. Fucoxanthin is of scientific interest because researchers have investigated its biological properties and potential roles in metabolic research.
The quantity of fucoxanthin in a commercial ingredient depends on the raw material, extraction and processing methods, and product standardization. The exact fucoxanthin content of Xanthigen® should therefore be taken from the current manufacturer specification rather than inferred from general information about wakame.
Pomegranate seed oil is obtained from the seeds of Punica granatum. It contains a distinctive fatty-acid profile and other naturally occurring constituents. Its composition can vary with the source material, processing method, and quality specifications.
In Xanthigen®, pomegranate seed oil forms part of the proprietary combination with the wakame-derived component. The ingredient's commercial identity and formulation should be distinguished from generic pomegranate seed oil or generic fucoxanthin extracts.
Xanthigen® is positioned for nutraceutical and dietary supplement product development, particularly in weight-management-oriented formulations. Depending on the manufacturer's technical documentation and the applicable market regulations, formulators may evaluate it for capsules, tablets, powder blends, or other suitable finished-product formats.
The appropriate format depends on the ingredient's physical properties, compatibility with excipients, processing conditions, stability, sensory characteristics, and recommended inclusion level. Manufacturers should confirm these details before selecting the ingredient for a commercial formulation.
The quality of a proprietary botanical ingredient depends on its identity, manufacturing process, standardization, purity, stability, and batch-to-batch consistency. Buyers should request the current Technical Data Sheet, Safety Data Sheet where applicable, Certificate of Analysis, ingredient declaration, recommended use guidance, storage instructions, and relevant quality documentation.
For Xanthigen®, particular attention should be given to the declared botanical identity, fucoxanthin standardization if specified, characteristics of the pomegranate seed oil component, and the finished ingredient's analytical acceptance criteria.
The Xanthigen® developer describes the ingredient as a proprietary combination developed for weight-management applications and references human clinical research. Any claim about weight loss, body fat, energy expenditure, cholesterol, blood pressure, or other physiological outcomes must be evaluated against the actual supporting research, applicable advertising requirements, and the regulatory status of the finished product.
A study of a specific ingredient formulation does not automatically establish the same outcome for every supplement containing that ingredient. Results can depend on the study design, participants, amount consumed, duration, background diet, and other factors. Avoid presenting the ingredient as a treatment for obesity or another medical condition unless such a claim is specifically authorized in the relevant market.
Businesses interested in Xanthigen® should confirm product availability, authorization to distribute the branded ingredient, minimum order quantity, packaging, lead time, storage requirements, and applicable commercial terms.
Mediocon Inc. can publish product information and respond to sourcing enquiries according to its verified supply arrangements. Before a quotation is issued, the buyer and supplier should confirm the exact branded material, current specification, intended application, destination market, and required documentation.
Xanthigen® is a proprietary nutraceutical ingredient developed by Nektium that combines a wakame brown seaweed-derived component with pomegranate seed oil. It is positioned for weight-management-oriented formulation development. Accurate product information should emphasize its proprietary identity, verified composition, technical specifications, quality documentation, and responsible use of evidence-based claims.
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Xanthigen® Nutraceutical Ingredient | Manufacturer | Mediocon Inc. and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Xanthigen® Nutraceutical Ingredient | Manufacturer | Mediocon Inc. is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance